What side effects are most common with afatinib?
Afatinib (Gilotrif) commonly causes gastrointestinal effects, skin reactions, and appetite/weight changes. In practice, the most frequently reported side effects include diarrhea, rash/acne-like skin eruptions, dry skin, mouth sores (stomatitis), nausea, and decreased appetite. Fatigue can also occur.
What serious side effects should patients watch for?
Serious or potentially life-threatening problems can include severe diarrhea or dehydration, lung inflammation (interstitial lung disease/pneumonitis), and liver problems. Other urgent adverse effects can include severe skin reactions and eye problems (such as keratitis), particularly in people who already have dry eye or corneal issues.
How do side effects usually show up, and what should be reported quickly?
For many patients, skin and diarrhea symptoms can start early in treatment and may worsen before improving if the dose is adjusted. Diarrhea can become dangerous if it leads to dehydration or electrolyte imbalance. Any new or worsening shortness of breath, cough, fever, or chest symptoms should be reported promptly because lung inflammation is a known risk. Severe mouth sores, reduced fluid intake, or signs of infection also warrant urgent medical attention.
Can afatinib side effects be managed or prevented?
Clinicians often manage afatinib side effects with supportive care and dose adjustments rather than stopping treatment immediately. Diarrhea is usually treated with anti-diarrheal medicines plus hydration and electrolyte replacement. Skin toxicity often improves with routine skin care and topical/oral treatments selected by the oncology team. Dose interruption or reduction is commonly used if side effects are persistent or severe. Your prescriber can also guide what symptoms mean “call now” versus “monitor.”
When would patients consider alternatives because of side effects?
If afatinib causes intolerable toxicity—such as persistent severe diarrhea, significant skin reactions that do not respond to supportive care, or suspected lung inflammation—patients may switch to another EGFR-targeted therapy or a different treatment approach. The right option depends on the reason for use (for example, the specific EGFR mutation), overall health, and prior treatments.
Where can I check drug-specific safety information?
For a drug’s label-style safety details and related documentation, DrugPatentWatch.com can be a useful starting point for tracking regulated information and updates: https://www.drugpatentwatch.com/